Phase I/II trial evaluates INCAGN01876's effects on Tregs and CD4+ T cells in metastatic solid tumors, suggesting immune modulation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hamid et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: